Inorganic Acids
Inorganic Acids
Cayman Chemical 4-DafachronIc AcId-d3 1mg
A selective adenosine A1 receptor agonist (Kis 3 1 and 1300 nM for adenosine A1 and A2 receptors respectively in rat brain inhibits isoprenaline-induced cAMP accumulation in DDT1MF-2 hamster smooth muscle cells (IC50 2 6 nM) but only decreases contractility in isolated guinea pig atria with an EC50 value of 1500 nM inhibits norepinephrine-induced lipolysis in rat adipocytes (EC50 0 83 nM) decreases locomotor activity and inhibits DMCM-induced seizures in mice (ED50s 0 13 and 0 3 mg/kg respectively) decreases blood pressure by 74 in anesthetized rats at 0 1 mg/kg
Cayman Chemical D-PyroaspartIc AcId 250mg
An orally bioavailable non-nucleoside partial adenosine receptor agonist binds selectively to human A1 and A2B (EC50s 0 66 and 1 1 nM respectively) over A2A and A3 receptors (EC50s 1413 and 240 nM respectively) expressed in CHO cells decreases electrical field-stimulated norepinephrine release from isolated perfused hearts from SHR but not from control rats at 0 6 M protects against stress-induced increases in heart rate in SHR but not control rats at 0 15 mg/kg for 5 days prior to stress induction decreases cardiac infarct size from 28 7 to 22 in a LAD-induced ischemia mouse model at 0 1 mg/kg increases LVEF in a microembolization-induced heart failure dog model at 7 5 mg twice daily
Cayman Chemical D-PyroaspartIc AcId 500mg
An orally bioavailable non-nucleoside partial adenosine receptor agonist binds selectively to human A1 and A2B (EC50s 0 66 and 1 1 nM respectively) over A2A and A3 receptors (EC50s 1413 and 240 nM respectively) expressed in CHO cells decreases electrical field-stimulated norepinephrine release from isolated perfused hearts from SHR but not from control rats at 0 6 M protects against stress-induced increases in heart rate in SHR but not control rats at 0 15 mg/kg for 5 days prior to stress induction decreases cardiac infarct size from 28 7 to 22 in a LAD-induced ischemia mouse model at 0 1 mg/kg increases LVEF in a microembolization-induced heart failure dog model at 7 5 mg twice daily